The UK and US have signed a important commercial pact that will guarantee no levies on British medicine products going into the US market.
Key Provisions of the Pact
As part of the deal, the UK has committed to raise funding on drugs through the public health system. This move ensures that tariffs on these crucial goods will stay at zero for a duration of three years.
This development comes after earlier statements to dramatically increase duties on branded pharmaceutical imports, with figures floated as high as double the cost.
"This deal with the UK reinforces the international landscape for innovative medicines and brings long-overdue fairness to transatlantic medicine commerce," a statement said.
Commercial Impact
Pharmaceuticals are one of the UK's most significant goods shipped to the America, which is easily the primary buyer for major companies like GSK and AstraZeneca.
Trade data indicate that in the 12 months leading up to last September, the UK sold drugs totaling £11.1bn to the US. This value accounted for 17.4% of all goods exports in that period.
"This guarantee safeguards work, boosts funding and facilitates the UK to establish itself as a global hub for life sciences," a government official commented.
Specific NHS Changes
The pact involves several key commitments from the British government:
- Price Threshold Increase: The UK will increase the price threshold at which it judges new treatments to be prohibitively costly by 25%.
- Increased NHS Spending: There is a target to increase overall public funding on drugs from 0.3% of GDP to 0.6 percent over the next decade.
- Payback Limit: The percentage drug companies must refund to the NHS to control costs will be capped at fifteen percent. Last year, refunds exceeded twenty percent.
Recent Tensions
This agreement comes amid a protracted row between the sector and the UK government over medicine costs and regulatory access.
The disagreement were intensified by arguments that US consumers were paying a premium for the identical medicines than people in the UK and Europe.
Recently, several large pharmaceutical investments in the UK have been halted or abandoned, while major investments have been pledged toward US facilities.
The Science Minister stated that the NHS had to increase expenditure on drugs, noting that its spending on drugs had declined as a proportion of its total funding over the previous ten-year period.
